Life science VC investor Epidarex outdoes Fund III size at first close of Fund IV, pulls in $145m to date

Life sciences-focused venture capital firm Epidarex Capital has picked up more than $145m of commitments at the first close of its fourth flagship fund, putting it above the predecessor vehicle it raised in 2020.